Nectar Lifesciences Limited Buyback 2025

1. Pharmaceutical manufacturer & CRO services — Nectar Lifesciences operates as an API (active pharmaceutical ingredients) and finished-dosage formulation manufacturer, offering contract research and manufacturing services (CRAMS) and supplying to domestic and global drug companies.

2. Global presence — The company exports a significant portion of its products to regulated international markets, giving it exposure beyond India.

3. Integrated manufacturing facilities — It has in-house capabilities covering the full value chain from drug development to commercial-scale manufacturing, which helps manage quality, compliance and cost.

4. Regulatory compliance & quality standards — Nectar maintains compliance with international regulatory standards (e.g. for exports), positioning it as a reliable supplier to global pharma partners.

5. Diversified product portfolio — It produces a range of APIs and formulations across therapeutic segments, reducing dependency on any single product or client.

6. Growth potential in CRAMS & generics demand — With increasing global outsourcing of pharmaceutical manufacturing and demand for generic drugs, Nectar is well placed to benefit from shifts in global supply-chain dynamics.

Buy Back Offer Deal:

Buyback Type: Tender Offer
Buyback Record Date: Dec 24 2025
Buyback Offer Amount: ₹ 81 cr
Date of Board Meeting approving the proposal: Dec 03 2025
Date of Public Announcement: Dec 03 2025
Buyback Offer Size: 13.38%
Buyback Number of Shares: 3,00,00,000
FV: 1
Buyback Price: ₹ 27 Per Equity Share

Details of Buyback:

The proposal to buyback not exceeding 3,00,00,000 (Three crore only) equity shares of the Company (representing 13.38% of the total number of equity shares in the paid up share capital of the Company) at a price of  Rs. 27/- (Rupees Twenty Seven Only) per equity share payable in cash for an aggregate consideration not exceeding Rs. 81,00,00,000/- (Indian Rupees Eighty-one crore only)

Salient financial parameters:

Particulars (in Cr) Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Sales + 1,541 1,665 1,520 1,682 1,664
Expenses + 1,432 1,507 1,467 1,530 1,694
Operating Profit 109 159 53 152 -30
OPM % 7% 10% 3% 9% -2%
Other Income + -22 11 43 15 5
Interest 112 79 79 87 75
Depreciation 60 57 59 61 62
Profit before tax -85 34 -42 18 -162
Tax % -14% 26% -43% 73% -30%
Net Profit + -73 25 -24 5 -114
EPS in Rs -3.27 1.12 -1.08 0.22 -5.07
Dividend Payout % 0% 0% 0% 0% 0%

How to Participate in buyback?

1. Firstly, to be eligible for the buyback the investor should have shares Nectar Lifesciences Limited in Demat or physical form as on the record date [24-12-2025]. 2. Once you have shares in Demat, you can participate in the buyback process which is opening from [To be updated] by selling your shares through your broker on NSE or BSE 3. Then on [To be updated], the payment will be given to you for accepted shares and unaccepted shares will be returned to your Demat account.

7 Comments

    Any reason for so many buybacks,I mean last time I saw something list this on sep-Oct 2024 because of taxation on bb.

    Reply

    eClerx Services has fixed 17 December 2025 as record date to determine the equity shareholders who would be eligible to participate in the buy back of shares

    Reply

      maximum buyback amt can be 59crore as per their latest BS and cash reserves are 40crore… low AR expected

      Reply

    Hello sir, I have a question that can we buy it for more than 2.0 lacs to enter in general category as promotor is not participating and FII and DII are very small and 85% will be reserved for general category so may be acceptance ratio for general category remains high as HNI people generally avoid buyback due to tax calculation and assuming that most people having stocks of more than 2.0 lacs would be HNI

    Reply

Leave a Reply